Internal Medicine
M-A | Midodrine for the prevention of vasovagal syncope.
30 Aug, 2022 | 11:56h | UTCRelated: RCT: Midodrine can reduce the recurrence of vasovagal syncope.
Cohort Study | Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis.
30 Aug, 2022 | 11:53h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1562922771730305030
#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.
29 Aug, 2022 | 12:38h | UTCPercutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology
Commentary on Twitter
REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
#ESCCongress – RCT | Routine functional testing is not better than standard care in high-risk patients after percutaneous coronary intervention.
29 Aug, 2022 | 12:32h | UTCRoutine Functional Testing or Standard Care in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
POST-PCI: In a randomized trial of patients who underwent percutaneous coronary intervention, routine stress testing did not improve clinical outcomes at two years. #ESCCongress https://t.co/nil00HQm4Z pic.twitter.com/o4v0UcDfYV
— NEJM (@NEJM) August 28, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
29 Aug, 2022 | 12:25h | UTCAcetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology
Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology
Commentary on Twitter
https://twitter.com/NEJM/status/1563421082505588738
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
#ESCCongress | 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
29 Aug, 2022 | 12:21h | UTCNews Release: People of all ages should learn cardiopulmonary resuscitation – European Society of Cardiology
#ESCCongress | 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.
29 Aug, 2022 | 12:22h | UTCNews Release: All patients over 65 years should have a heart check before high-risk non-cardiac surgery – European Society of Cardiology
#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.
29 Aug, 2022 | 12:24h | UTCFive-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology
Commentary on Twitter
DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK
— NEJM (@NEJM) August 27, 2022
#ESCCongress | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
29 Aug, 2022 | 12:18h | UTCNews Release: Pulmonary hypertension guidelines call for earlier diagnosis – European Society of Cardiology
#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, targeting a mean arterial blood pressure of 77 mmHg vs. 63 mmHg did not result in different outcomes.
29 Aug, 2022 | 12:13h | UTCBlood-Pressure Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial finds no benefit of raising blood pressure target in post cardiac arrest patients – European Society of Cardiology
Commentary: Blood Pressure Targets Show No Benefit in Comatose Survivors of Cardiac Arrest – HCPLive
Commentary on Twitter
BOX BP: This randomized trial found no difference in the rate of death or severe disability/coma when patients following out-of-hospital cardiac arrest were managed with higher or lower blood pressure targets. #ESCCongress https://t.co/5qOMtiPSck pic.twitter.com/QOl5KetTvn
— NEJM (@NEJM) August 27, 2022
[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.
29 Aug, 2022 | 12:15h | UTCCommentary:
ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD
No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now
#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, a restrictive vs. a liberal oxygenation strategy resulted in similar incidences of death, severe disability, and coma.
29 Aug, 2022 | 12:12h | UTCOxygen Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Restrictive oxygenation in post cardiac arrest patients is not harmful – European Society of Cardiology
Commentary on Twitter
BOX Oxygen: This RCT found no difference in the rate of death or severe disability/coma when mechanically ventilated patients following out-of-hospital cardiac arrest were managed with higher or lower oxygenation targets. #ESCCongress https://t.co/qqtd4SyVrl pic.twitter.com/q73gqSuAn4
— NEJM (@NEJM) August 27, 2022
Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
29 Aug, 2022 | 12:11h | UTCAutoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)
Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress
Meta-analysis of randomized trials | Intensive vs. short face-to-face smoking cessation interventions.
29 Aug, 2022 | 12:03h | UTC
Systematic Review | There is little evidence to guide interventions for preventing and reducing the use of physical restraints on older people in general hospital settings.
29 Aug, 2022 | 12:01h | UTC
Network Meta-Analysis | Antithrombotic therapy for symptomatic peripheral arterial disease.
26 Aug, 2022 | 13:28h | UTC
RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.
26 Aug, 2022 | 13:29h | UTCEffectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco
Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist
Commentary on Twitter
Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC
— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022
RCT | Efficacy of potassium supplementation on the risk of peritonitis in hypokalemic patients receiving peritoneal dialysis.
26 Aug, 2022 | 13:25h | UTCEfficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial – American Journal of Kidney Diseases (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/AJKDonline/status/1528677142036455425
Secondary analysis of a RCT | Effects of Empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.
26 Aug, 2022 | 13:24h | UTCCommentary: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay
Original Study: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine